Lon protease, alpha-hemolysin, ck1-alpha-1; c-myb inhibitor or a cebp-delta inhibitor as therapeutics
AssigneeLinnane Pharma AB
InventorsCatharina SVANBORG, Daniel Sebastian Christopher BUTLER
Life of this patent
Estimating the term…
Abstract
A therapeutic agent comprising Lon protease, or a variant or active fragment thereof, alpha-hemolysin, or a variant or active fragment thereof, CK1α1, or a variant or active fragment thereof, a c-MYB inhibitor and/or a CEBP-δ inhibitor, for use in therapy, with the proviso that the therapeutic agent does not comprise a bacteria or bacterial supernatant. Methods of production and use thereof.
Claims17
A therapeutic agent comprising Lon protease, or a variant or active fragment or equivalent thereof;
- alpha-hemolysin, or a variant or active fragment or equivalent thereof;
- CK1α1, or a variant or active fragment or equivalent thereof;
- a c-MYB inhibitor or a CEBP-δ inhibitor;
- or combination thereof, for use in therapy, with the proviso that the therapeutic agent does not comprise a bacteria or bacterial supernatant or lysate.
A therapeutic agent for use according to any preceding claim, comprising isolated Lon protease, or a variant or active fragment or equivalent thereof, isolated alpha-hemolysin, or a variant or active fragment or equivalent thereof, isolated CK1α1, or a variant or active fragment or equivalent thereof, an isolated c-MYB inhibitor and/or an isolated CEBP-δ inhibitor.
A therapeutic agent for use according to any preceding claim, comprising synthetic Lon protease, or a variant or active fragment or equivalent thereof, synthetic alpha-hemolysin, or a variant or active fragment or equivalent thereof, synthetic CK1α1, or a variant or active fragment or equivalent thereof, a synthetic c-MYB inhibitor and/or a synthetic CEBP-δ inhibitor
A therapeutic agent for use according to any preceding claim, wherein the c-MYB inhibitor and/or CEBP-δ inhibitor are proteins or variants or active fragments thereof.
A therapeutic agent for use according to any preceding claim, wherein the use is treatment or prevention of a disease wherein c-MYC levels are elevated.
A therapeutic agent for use according to any preceding claim, wherein the use is treatment or prevention of cancer and/or infection, preferably wherein the cancer is lymphoma, epithelial cancer or mucosal cancer, preferably wherein the infection is of the urinary tract.
A therapeutic agent for use according to any preceding claim, wherein the c-MYB inhibitor and/or a CEBP-δ inhibitor are inhibitors of c-MYB and/or CEBP-δ expression.
A recombinant microorganism engineered to express elevated levels of Lon protease, or a variant or active fragment or equivalent thereof, alpha-hemolysin, or a variant or active fragment or equivalent thereof, CK1α1, or a variant or active fragment or equivalent thereof, a c-MYB inhibitor and/or a CEBP-δ inhibitor.
A microorganism extract obtained from a recombinant microorganism according to claim 10.
A kit comprising isolated Lon protease, or a variant or active fragment or equivalent thereof, isolated alpha-hemolysin, or a variant or active fragment or equivalent thereof, isolated CK1α1, or a variant or active fragment or equivalent thereof, an isolated c-MYB inhibitor and/or an isolated CEBP-δ inhibitor.
Dependencies are inferred from the claim text.